Figure 3: Immunohistochemistry (IHC) and Immunofluorescence (IF) analysis of MD2 expression and immune cell infiltration in prostate cancer tissues. (Upper panel) Representative IF images showing ...
Despite guidelines on bone protection, more than 40% of patients with metastatic castration-resistant prostate cancer received no bone-modifying agents, a US study found. The use has declined in ...
Morning Overview on MSN
A prostate cancer drug halved the odds of the disease spreading
Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...
Researchers at Baylor College of Medicine and collaborating institutions have developed a method that reveals the cellular makeup of tissues that support metastatic cancer growth, which is the primary ...
Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study The classification of patients with prostate cancer, based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results